Clinical Trials

Beyond First Line Therapy

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

LEARN MORE

Beyond First Line Therapy

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

LEARN MORE

Beyond First Line Therapy

ICP-CL-00303

LEARN MORE

Beyond First Line Therapy

Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC)

LEARN MORE

Beyond First Line Therapy

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)

LEARN MORE

Beyond First Line Therapy

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

LEARN MORE

Beyond First Line Therapy

Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

LEARN MORE

Beyond First Line Therapy

A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients with Advanced Biliary Tract Cancer (BTC)

LEARN MORE

Beyond First Line Therapy

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

LEARN MORE

Beyond First Line Therapy

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

LEARN MORE

Beyond First Line Therapy

Tree Topp

LEARN MORE

Beyond First Line Therapy

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

LEARN MORE